Propafenone is an antiarrhythmic agent with recognized cardiac myocyte repolarizing K ϩ current inhibitory effects. It has two known electropharmacologically active metabolites, 5-hydroxy-and N-depropylpropafenone, whose K ϩ current inhibitory effects are less thoroughly elucidated than those of the parent compound. This study characterizes and directly compares the pharmacologic interaction of all three compounds with two key repolarizing K ϩ currents, the rapidly activating delayed rectifier I Kr and the transient outward current I to , using the whole-cell patch-clamp technique in isolated rabbit ventricular myocytes. All three agents potently inhibited I Kr with IC 50 values of 0.80 Ϯ 0.14, 1.88 Ϯ 0.21, and 5.78 Ϯ 1.24 M for propafenone, 5-hydroxypropafenone, and N-depropylpropafenone, respectively, based on reduction of peak tail current amplitude following repolarization from ϩ50 mV to Ϫ30 mV. I Kr inhibition was concentration-and weakly voltage-dependent, with a time course from channel activation that was well described by a single exponential model and consistent with open channel block. Propafenone and its 5-hydroxy and N-depropyl metabolites also blocked I to with IC 50 values of 7.27 Ϯ 0.53, 40.29 Ϯ 7.55, and 44.26 Ϯ 5.73 M, respectively, at ϩ50 mV. No significant drug effects were observed with respect to I to voltage dependence of steady-state inactivation or time course of recovery from inactivation. The preferential interaction of propafenone and its metabolites with I Kr relative to I to in ventricular myocytes sheds new light on the anti-and proarrhythmic activity of propafenone in vivo.
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The Vaughan Williams class 1c antiarrhythmic agent propafenone inhibits cardiac myocyte repolarizing currents in a number of experimental preparations. Propafenone blocks the transient outward (I to ) and ultrarapidly activating delayed rectifier (I Kur ) currents in human (Gross and Castle, 1998; Seki et al., 1999) and rabbit (Duan et al., 1993) atrial myocytes as well as in adult (Slawsky and Castle, 1994) and neonatal (Cahill et al., 2001 ) rat ventricular myocytes. In guinea pig ventricular myocytes, propafenone potently and preferentially inhibits the rapidly activating component of delayed rectifier current, I Kr (Delpón et al., 1995) . Propafenone also blocks the heterologously expressed human cardiac K ϩ channel HERG, which mediates I Kr in living cardiac myocytes (Mergenthaler et al., 2001; Paul et al., 2002) .
Clinical use of propafenone is associated with extensive hepatic transformation of the parent agent to two electropharmacologically active metabolites, 5-hydroxypropafenone and N-depropylpropafenone (Hege et al., 1984; Latini et al., 1987; Malfatto et al., 1988) . Available studies with 5-hydroxypropafenone indicate potent I to inhibition in cultured neonatal rat ventricular myocytes (Cahill et al., 2001 ) and electropharmacologic effects in intact organisms and in vitro preparations consistent with inhibition of a number of cardiac myocyte ionic currents (von Philipsborn et al., 1984; Delgado et al., 1987; Valenzuela et al., 1987 Valenzuela et al., , 1988 Malfatto et al., 1988; Rouet et al., 1989; Case et al., 1991; Haefeli et al., 1991; Boucher et al., 1996; Franqueza et al., 1998) . The cardiac cellular electropharmacology of N-depropylpropafenone has not been previously studied, although limited data suggesting ionic current blockade are available from intact animals and tissue preparations (Malfatto et al., 1988; Rouet et al., 1989) .
We used the whole-cell patch-clamp technique to directly compare the inhibitory effects of propafenone, 5-hydroxypropafenone, and N-depropylpropafenone on the repolarizing currents I to and I Kr in isolated rabbit ventricular myocytes.
Materials and Methods
This investigation conformed with the Guide to the Care and Use of Experimental Animals published by the Canadian Council on Animal Care (2nd edition, 1993) and was approved by the University of Manitoba Protocol Management and Review Committee.
Rabbit Ventricular Myocyte Isolation. Healthy male New Zealand White rabbits (2.5-3.5 kg) were anesthetized with inhaled isoflurane followed by intravenous heparinization (500 IU). After rapid cardiectomy, the aorta was cannulated (Ͻ2 min) and perfused retrogradely at 27 ml/min with nominally Ca 2ϩ -free HEPES-buffered saline (HBS) solution until the return was clear (ϳ10 min). The atria, excess connective tissue, and pericardium were trimmed off. Fresh Ca 2ϩ -free HBS containing 1 mg/ml collagenase (class 2; Worthington Biochemicals, Freehold, NJ) and 0.14 mg/ml protease (type XIV; Sigma-Aldrich, St. Louis, MO) was then substituted and recirculated until the ventricles softened (15-20 min), followed by a 4-min washout with enzyme-and Ca 2ϩ -free HBS. All perfusates were gassed with 100% O 2 and maintained at 37 Ϯ 1°C. The ventricles were gently teased apart with forceps, dispersing the myocytes. The resulting suspension was filtered, then myocytes were resuspended in sequentially higher Ca 2ϩ concentrations (0.05, 0.1, 0.2, 1.0, and 1.8 mM in HBS) and stored at room temperature for study within 10 h of isolation.
Electrophysiologic Recording. Conventional whole-cell patch clamp was performed as previously described (Hamill et al., 1981; Gross et al., 1995) . Myocytes were allowed to settle to the bottom of a modified 35-mm culture dish mounted on the stage of an inverted microscope (Nikon Diaphot 300). The cells were superfused continuously at 1 to 2 ml/min. Only quiescent rod-shaped cells with clear striations were selected for study. Thin-walled borosilicate micropipettes were pulled and polished to a resistance of 1.5 to 3.0 M⍀ when filled with intracellular solution. Voltage-clamp protocols were controlled with a Pentium 133 MHz personal computer running pClamp 6.0.4 software interfaced to an Axopatch 200B amplifier via a Digidata 1200 A/D board (Axon Instruments Inc., Union City, CA). All experiments were carried out at room temperature (20 -22°C). Holding potential was Ϫ80 mV except as otherwise indicated, and Na ϩ current was inactivated with a 100-ms conditioning step to Ϫ50 mV prior to each test pulse. L-type Ca 2ϩ current was blocked with 2 mM CoCl 2 in the extracellular solution.
Solutions and Reagents. HBS used in ventricular myocyte isolation contained 132 mM NaCl, 4 mM KCl, 1.2 mM MgCl 2 , 10 mM HEPES, 10 mM D-glucose, and 0.5% bovine serum albumin, pH 7.4 with NaOH. The extracellular solution used for whole-cell patchclamp recording included 135 mM NaCl, 5.4 mM KCl, 2.0 mM CoCl 2 , 1.0 mM CaCl 2 , 1.0 mM MgCl 2 , 10 mM HEPES, and 10 mM D-glucose, pH 7.4 with NaOH. Pipette solution consisted of 145 mM KCl, 5 mM NaCl, 5 mM K 2 EGTA, 10 mM HEPES, and 4 mM MgATP, pH 7.2 with KOH. Propafenone, 5-hydroxypropafenone, and N-depropylpropafenone (Knoll Pharma, Markham, ON, Canada) were kept as 10-mM stock solutions in dimethyl sulfoxide and serially diluted in control extracellular solution as required. E-4031 (Wako Pure Chemicals, Osaka, Japan) was stored as 5 mM stock solution dissolved in water then diluted to 5 M in extracellular solution. All stock drug solutions were stored at Ϫ20°C until dilution to appropriate concentrations on the day of use. With any change in extracellular solution, at least 5 ml of the new solution were perfused through the bath to allow for equilibration prior to electrophysiologic recording.
Data Analysis. I Kr was measured as peak tail current density at Ϫ30 mV following 3-s depolarizing voltage steps from a holding potential of Ϫ80 mV (Salata et al., 1996) . To ensure that our measurements of I Kr inhibition by propafenone and its metabolites were not confounded by I Ks , we excluded data obtained from cells in which any of the following were observed: 1) evidence of multiple currents in an envelope of tails test; 2) the presence of a second deactivating tail current at 0 mV suggestive of I Ks according to a protocol described by Carmeliet (1998) ; and/or 3) failure to observe complete tail-current inhibition with application of the dofetilide analog E-4031 at 5 M (Follmer and Colatsky, 1990 ).
Transient outward current (I to ) and its inhibition were analyzed as previously described (Gross and Castle, 1998; Cahill et al., 2001) . Briefly, I to was measured as the time integral of spontaneously decaying outward current observed in response to depolarizing 800-ms voltage steps from a holding potential of Ϫ80 mV, adjusted for the "steady-state" current remaining at the end of the step.
Dose-response curves were generated using the Hill equation. I to inactivation time constants were obtained using single or double exponential decay models fitted to the raw current tracings. Steadystate voltage dependence of I to inactivation data were fitted with the Boltzmann equation, and the time course of recovery from inactivation with a single exponential equation. All curve-fitting procedures were performed using Origin 6.0 (OriginLab Corp., Northampton, MA), yielding time constants and midpoint potentials for pooled data where appropriate. Results are reported as mean Ϯ S.E. except as otherwise indicated.
Results

I Kr Inhibition by Propafenone and Its Metabolites.
In response to 3-s depolarizing voltage steps from a holding potential of Ϫ80 mV followed by repolarization to Ϫ30 mV, we observed a time-dependent outward current followed by a deactivating tail current (Fig. 1) . Although Salata and colleagues (1996) have shown evidence of the slowly activating component I Ks in this preparation, the delayed rectifier current expressed in myocytes studied here featured characteristics consistent with those of pure I Kr .
Propafenone and its metabolites potently inhibited I Kr in a concentration-dependent fashion (Fig. 2) . Based on reduction of peak tail current amplitude following repolarization from ϩ50 mV to Ϫ30 mV, IC 50 values of 0.80 Ϯ 0.14, 1.88 Ϯ 0.21, and 5.78 Ϯ 1.24 M were calculated for propafenone, 5-hydroxypropafenone, and N-depropylpropafenone, respectively (Fig. 3A) . Figure 3B illustrates I Kr tail current density-voltage relations in the absence and presence of increasing concentrations of propafenone.
Voltage-dependent I Kr inhibition is consistent with open channel blockade and has previously been reported with Representative illustration of family of tracings elicited with a series of 3-s depolarizing voltage steps from a holding potential of Ϫ80 to Ϫ40, Ϫ20, 0, ϩ20, ϩ40, and ϩ60 mV (inset), followed in each case by repolarization to Ϫ30 mV to elicit outward tail current.
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Cahill and Gross at ASPET Journals on July 7, 2017 jpet.aspetjournals.org dofetilide in rabbit and guinea pig (Carmeliet, 1992) and with propafenone in guinea pig (Delpón et al., 1995) ventricular myocytes. In the present study involving rabbit ventricular myocytes, tail current inhibition was mildly voltage-dependent with all three agents tested (Fig. 4A) . Further evidence of open channel blockade was provided by estimation of the time course of I Kr inhibition, through comparison of tail current amplitudes following depolarizations of varying duration in the absence and presence of drug. As can be seen in Fig. 4B , the time course of I Kr inhibition was well described by a single exponential model. Furthermore, tail currents following relatively short depolarizations in the presence of drug were essentially the same as control currents, indicating lack of tonic I Kr blockade by these agents.
I to Inhibition by Propafenone and Its Metabolites. A rapidly activating, slowly inactivating current characteristic of I to was elicited with 800-ms depolarizations from a holding potential of Ϫ80 mV. Although propafenone itself predictably inhibited this current in a concentration-and time-dependent fashion similar to that seen in other preparations (Duan et al., 1993; Slawsky and Castle, 1994; Gross and Castle, 1998) (Fig. 5A) , both the 5-hydroxy and N-depropyl metabolites did so far less potently. The IC 50 for propafenone was 7.27 Ϯ 0.53 M at ϩ50 mV, whereas 5-hydroxypropafenone and N-depropylpropafenone blocked I to with IC 50 values of 40.29 Ϯ 7.55 and 44.26 Ϯ 5.73 M, respectively, at ϩ50 mV (Fig. 5B) . Unlike propafenone inhibition of I to , which was promptly and completely reversible upon washout (Fig. 6A) , blockade by the metabolites was only partially reversible (Fig. 6B) .
Previous studies have shown no significant effect of propafenone on I to voltage dependence of steady-state inac- Fig. 2 . Voltage-gated activating and tail currents elicited in the absence (left-hand panels) and presence (right-hand panels) of 30 M propafenone (A), 5-hydroxypropafenone (5-OHpropaf; B), and N-depropylpropafenone (N-DPpropaf; C), using the same voltage-step protocol as in Fig. 1 . Currents that persist after drug application in the depolarization phase of each tracing represent inwardly rectifying current (I K1 ) activated at voltages negative to 0 mV, which was not significantly inhibited by any of the agents tested.
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at ASPET Journals on July 7, 2017 jpet.aspetjournals.org tivation or time course of recovery from inactivation. In the present study, neither propafenone nor either of the metabolites studied had any apparent effect on these phenomena. None of the compounds studied showed use dependent I to block.
Discussion
Clinical Significance of Repolarizing Current Blockade by Propafenone and Its Metabolites. Propafenone is effective in the medical therapy of a variety of supraventricular as well as ventricular tachyarrhythmias in children (Paul and Janousek, 1994) and adults (Grant, 1996) . Although categorized as a sodium channel-blocking agent in the Vaughan Williams antiarrhythmic drug classification scheme, propafenone potently inhibits a number of repolarizing potassium currents in cardiac myocytes isolated from humans (Gross and Castle, 1998; Seki et al., 1999) as well as from animals (Duan et al., 1993; Slawsky and Castle, 1994; Delpón et al., 1995; Christé et al., 1999; Cahill et al., 2001 ). Most repolarizing current investigations have focused on I to inhibition (Duan et al., 1993; Slawsky and Castle, 1994; Gross and Castle, 1998; Seki et al., 1999; Cahill et al., 2001 ). However, more recent studies involving heterologously expressed HERG channels, which mediate I Kr , suggest that HERG is an important molecular target for propafenone (Mergenthaler et al., 2001; Paul et al., 2002) . This supports the earlier demonstration of guinea pig ventricular myocyte I Kr inhibition by Delpón et al. (1995) and is of great interest because I Kr inhibition likely plays a key role in sometimes Fig. 3 . Concentration-dependent I Kr inhibition by propafenone and its metabolites. A, dose-response curves for propafenone, 5-hydroxypropafenone, and N-depropylpropafenone generated from pooled peak tail current data elicited during repolarization to Ϫ30 mV from 3-s steps to ϩ50 mV (n ϭ 3-9 for each data point) fitted with the Hill equation. Each raw data point was generated by normalizing the observed peak tail current following depolarization to ϩ50 mV in the presence of the drug, at the concentration indicated, to the current elicited in the same cell prior to drug application. B, current densityvoltage relations for I Kr peak tail currents in the absence (control, n ϭ 14) and presence of 0.1 (n ϭ 5), 1.0 (n ϭ 9), and 10 (n ϭ 4) M propafenone. propafenone (N-DPpropaf, triangles; n ϭ 3). The I Kr peak tail current amplitude in the presence of drug was divided by that recorded in the absence of drug to yield an estimate of residual current following 3-s steps to the voltages indicated. I Kr block by all three drugs was voltage-dependent to a similar extent. B, time dependence of I Kr block by 1 M 5-hydroxypropafenone. Depolarizing steps to ϩ50 mV of varying duration were applied in the presence of the drug, followed by repolarization to Ϫ30 mV to elicit tail current. For each cell (n ϭ 3), peak tail-current density was divided by the value obtained with a full 3-s depolarizing step prior to drug application and then plotted against depolarizing step duration in presence of the drug. The resulting curve is well fitted by a single exponential decay model with time constant () as shown and is consistent with a requirement for the channel to open in order for drug interaction to take place.
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Cahill and Gross at ASPET Journals on July 7, 2017 jpet.aspetjournals.org lethal proarrhythmic effects of antiarrhythmic drugs, including propafenone (Sanguinetti et al., 1995) . Thus, a primary aim of the present study was to directly compare the I to -and I Kr -blocking effects of propafenone in an isolated ventricular myocyte model reliably expressing both currents.
Role of the Metabolites 5-Hydroxy-and N-Depropylpropafenone. Clinical use of propafenone is associated with extensive hepatic metabolism (Hege et al., 1984) to products that include two substances with recognized electropharmacologic activity in cardiac muscle preparations, namely 5-hydroxy-and N-depropylpropafenone (Malfatto et al., 1988; Thompson et al., 1988; Rouet et al., 1989) . The extent of propafenone metabolism is phenotype-dependent (Siddoway et al., 1987) but can result in steady-state plasma concentrations of 5-hydroxy-and N-depropylpropafenone that are 18 and 23%, respectively, of that of the parent compound, with delayed metabolite clearance after discontinuation of propafenone administration (Kates et al., 1985) . Moreover, Latini and colleagues (1989) demonstrated that 5-hydroxypropafenone accumulates in human atrial muscle with even greater affinity than does propafenone, resulting in cardiac tissue metabolite concentrations that can match or exceed those of the parent drug. Almost no information on the cardiac myocyte repolarizing current inhibitory effects of 5-hydroxy-and N-depropylpropafenone has thus far been available. Characterization of propafenone metabolite interaction with I to and I Kr was therefore the second major aim of this work.
Propafenone and Its Metabolites Preferentially Inhibit I Kr Relative to I to . A key finding of the present study is that all three substances assessed preferentially inhibit I Kr relative to I to , a phenomenon that is even more pronounced in the metabolites than in the parent compound. The IC 50 value of 0.80 Ϯ 0.14 M obtained for I Kr tail-current blockade by I to inhibition by propafenone and its metabolites. A, following a Na ϩ current-inactivating 100-ms step to Ϫ35 mV from holding potential Ϫ80 mV, an 800-ms step to ϩ50 mV elicited I to under control conditions (voltage protocol, inset) . The myocyte was then sequentially superfused to presumed steady state (minimum 5 ml) with extracellular solution containing 1, 10, and 100 M propafenone as shown, resulting in marked concentration-and time-dependent I to block upon repetition of the voltage protocol. B, dose-response curves for propafenone, 5-hydroxypropafenone, and N-depropylpropafenone generated from pooled data at ϩ50 mV (n ϭ 3-8 for each data point) fitted with the Hill equation. Fig. 6 . Reversibility of I to blockade by propafenone (A) and 5-hydroxypropafenone (5-OHP; B). Control current was elicited with a ϩ50-mV depolarizing step in the absence of drug then repeated after extracellular drug application and equilibration at the concentration indicated. Drug-free extracellular solution (minimum 5 ml) was then applied to effect drug washout, resulting in nearly complete restoration of I to after propafenone exposure but only partial recovery after perfusion with either metabolite (N-depropylpropafenone not shown).
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propafenone in our freshly isolated rabbit ventricular myocytes is remarkably similar to the 0.44 Ϯ 0.07 M value documented by Paul and colleagues (2002) using cloned HERG channels stably expressed in mammalian HEK293 cells. Interestingly, these investigators found that propafenone was equipotent to quinidine in its inhibition of HERG currents and more potent than either flecainide or lidocaine, the other agents assessed in their study. Moreover, these values fall essentially within a clinically relevant therapeutic free plasma propafenone concentration range estimated at 0.15 to 0.7 M (Slawsky and Castle, 1994) . Mergenthaler et al. (2001) reported an IC 50 value of 13 to 15 M from their conventional two-electrode voltage-clamp study using HERG channels expressed in Xenopus laevis oocytes but cited work from their own laboratory indicating that the oocyte expression system typically demands antiarrhythmic drug concentrations 5-to 10-fold higher than those applied to mammalian cell lines to yield comparable inhibitory effects (Rolf et al., 2000) . There are no published data with which to compare the I Kr -blocking effects that we observed for 5-hydroxy-and Ndepropylpropafenone with IC 50 values of 1.88 Ϯ 0.21 M and 5.78 Ϯ 1.24 M, respectively. Although suggesting slightly less HERG-blocking potency than that of propafenone itself, the clinical relevance of these results is difficult to assess because of scant data relating to variations in plasma and tissue accumulation already mentioned.
Although our findings indicate significantly less potent inhibition of cardiac myocyte I to than of I Kr by propafenone itself, they are consistent with previous observations of propafenone I to inhibition in a variety of experimental models. The adult rabbit ventricular myocyte IC 50 value of 7.3 M reported here compares with previously documented values of 5.9 M in rabbit atrial myocytes (Duan et al., 1993) , 4.8 (Gross and Castle, 1998) and 4.9 (Seki et al., 1999 ) M in human atrial myocytes, 3.3 M in adult rat ventricular myocytes (Slawsky and Castle, 1994) , and 2.1 M in neonatal rat ventricular myocytes (Cahill et al., 2001) . It is noteworthy that the highest IC 50 values appear in rabbit, the only species in this group in which I to is thought to be mediated primarily by Kv1.4 rather than Kv4.2/4.3 channels (Kä ä b et al., 1998; Wickenden et al., 1999) .
Study Limitations. By restricting our study to ventricular myocytes that expressed I Kr as the sole measurable component of delayed rectifier K ϩ current, we might have overlooked potentially important I Ks -blocking activity by propafenone and its metabolites. However, I Ks blockade is not associated with significantly altered repolarization in rabbit ventricle (Lengyel et al., 2001) , and preferential propafenone inhibition of I Kr relative to that of I Ks has previously been demonstrated in a preparation that more readily accommodates study of both current components (Delpón et al., 1995) . Rabbit ventricular myocytes were selected for this work because they prominently express I Kr , the current most often implicated in drug-induced or "acquired" cases of QT interval prolongation and associated torsades des pointes (Camm et al., 2000) , along with I to , a well established repolarizing current target for antiarrhythmic agents.
Another potential limitation relates to performance of experiments at ambient rather than physiologic temperature, which affects the kinetics of K ϩ channel gating. We chose these conditions because they match those under which almost all benchmark data used for comparison were obtained (Slawsky and Castle, 1994; Delpón et al., 1995; Gross and Castle, 1998; Seki et al., 1999; Cahill et al., 2001) .
Conclusion
This work significantly enhances preexisting knowledge of the cellular mechanisms of action of the antiarrhythmic agent propafenone and its electropharmacologically active metabolites. First, it establishes N-depropylpropafenone as a repolarizing K ϩ current blocker comparable in its effects to its sister metabolite 5-hydroxypropafenone. Secondly and more importantly, it indicates that both of these metabolites as well as their parent compound, propafenone, inhibit ventricular myocyte I Kr more potently than I to . Finally, it suggests that the combined in vivo effect of these three compounds may be even more preferentially selective for I Kr , as evidenced by the metabolites' reduced affinity for I to relative to that of propafenone.
